Royal Bank of Canada’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$97.4M Sell
531,377
-10,448
-2% -$1.93M 0.02% 637
2025
Q4
$95.4M Buy
541,825
+43,705
+9% +$7.14M 0.02% 668
2025
Q3
$69.8M Buy
498,120
+1,968
+0.4% +$266K 0.01% 856
2025
Q2
$62.3M Buy
496,152
+165,590
+50% +$20.6M 0.01% 829
2025
Q1
$45.2M Buy
330,562
+84,227
+34% +$12M 0.01% 844
2024
Q4
$37.7M Sell
246,335
-96,859
-28% -$16.3M 0.01% 972
2024
Q3
$66.5M Sell
343,194
-52,518
-13% -$11M 0.01% 694
2024
Q2
$91.7M Sell
395,712
-7,566
-2% -$1.64M 0.02% 549
2024
Q1
$87M Buy
403,278
+29,264
+8% +$6.85M 0.02% 573
2023
Q4
$96.8M Buy
374,014
+67,460
+22% +$16.6M 0.02% 538
2023
Q3
$78.8M Sell
306,554
-45,986
-13% -$12.3M 0.02% 536
2023
Q2
$100M Buy
352,540
+65,659
+23% +$19.5M 0.03% 476
2023
Q1
$79.8M Sell
286,881
-96,925
-25% -$26.8M 0.02% 522
2022
Q4
$106M Buy
383,806
+131,377
+52% +$37.1M 0.03% 453
2022
Q3
$67.4M Sell
252,429
-43,308
-15% -$9.2M 0.02% 547
2022
Q2
$60.3M Buy
295,737
+33,466
+13% +$6.84M 0.02% 595
2022
Q1
$55.2M Sell
262,271
-17,642
-6% -$3.84M 0.01% 703
2021
Q4
$67.2M Sell
279,913
-11,106
-4% -$2.86M 0.02% 685
2021
Q3
$82.4M Sell
291,019
-96,849
-25% -$31.7M 0.02% 560
2021
Q2
$134M Buy
387,868
+36,132
+10% +$10.9M 0.04% 398
2021
Q1
$98.4M Sell
351,736
-27,298
-7% -$7.36M 0.03% 461
2020
Q4
$92.8M Sell
379,034
-40,757
-10% -$10.5M 0.03% 474
2020
Q3
$119M Buy
419,791
+66,634
+19% +$18.6M 0.04% 350
2020
Q2
$94.5M Buy
353,157
+55,578
+19% +$16.7M 0.04% 377
2020
Q1
$94.1M Sell
297,579
-57,678
-16% -$17.5M 0.05% 312
2019
Q4
$105M Sell
355,257
-11,471
-3% -$3.18M 0.04% 378
2019
Q3
$85.4M Buy
366,728
+70,774
+24% +$16.5M 0.03% 406
2019
Q2
$69.2M Sell
295,954
-86,858
-23% -$20.1M 0.03% 463
2019
Q1
$90.5M Sell
382,812
-15,129
-4% -$4.76M 0.04% 374
2018
Q4
$120M Sell
397,941
-50,494
-11% -$16.1M 0.06% 290
2018
Q3
$158M Sell
448,435
-58,602
-12% -$20.2M 0.07% 247
2018
Q2
$147M Sell
507,037
-140,283
-22% -$39.4M 0.07% 246
2018
Q1
$177M Buy
647,320
+298,014
+85% +$92.5M 0.08% 208
2017
Q4
$111M Buy
349,306
+48,832
+16% +$15.7M 0.05% 308
2017
Q3
$94.1M Buy
300,474
+8,161
+3% +$2.42M 0.05% 322
2017
Q2
$79.3M Sell
292,313
-56,973
-16% -$15.1M 0.04% 362
2017
Q1
$95.5M Sell
349,286
-131,149
-27% -$37.1M 0.05% 292
2016
Q4
$136M Buy
480,435
+106,448
+28% +$31.6M 0.07% 220
2016
Q3
$117M Buy
373,987
+85,833
+30% +$25.4M 0.07% 246
2016
Q2
$69.7M Sell
288,154
-11,672
-4% -$3.08M 0.04% 351
2016
Q1
$78M Sell
299,826
-51,140
-15% -$13.5M 0.05% 312
2015
Q4
$108M Buy
350,966
+119,437
+52% +$34.3M 0.07% 220
2015
Q3
$67.6M Sell
231,529
-82,937
-26% -$27.4M 0.05% 260
2015
Q2
$127M Buy
314,466
+61,571
+24% +$24.7M 0.09% 173
2015
Q1
$107M Sell
252,895
-70,103
-22% -$27.6M 0.07% 190
2014
Q4
$110M Buy
322,998
+31,205
+11% +$10.1M 0.07% 206
2014
Q3
$96.5M Buy
291,793
+57,853
+25% +$19.1M 0.07% 217
2014
Q2
$73.8M Sell
233,940
-9,557
-4% -$2.88M 0.05% 265
2014
Q1
$74.5M Sell
243,497
-10,699
-4% -$3.4M 0.05% 251
2013
Q4
$71.1M Buy
254,196
+47,181
+23% +$12.2M 0.05% 284
2013
Q3
$49.8M Sell
207,015
-133,637
-39% -$29.9M 0.04% 352
2013
Q2
$73.3M Buy
+340,652
New +$72.8M 0.06% 227

Other funds holding BIIB

Royal Bank of Canada's BIIB Position: Q1 2026 in Review

Royal Bank of Canada reduced its Biogen (BIIB) stake by 1.9% in Q1 2026, selling an estimated $1.93M and leaving 531,377 shares worth $97.4M. The position accounts for 0.02% of the portfolio, ranked #637.

Royal Bank of Canada first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $177M in Q1 2018. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Royal Bank of Canada held 531,377 shares of Biogen worth $97.4M as of Q1 2026.
  • Royal Bank of Canada sold 10,448 Biogen shares in Q1 2026, an estimated $1.93M.
  • Biogen made up 0.02% of Royal Bank of Canada's portfolio in Q1 2026, its #637 holding.
  • Royal Bank of Canada first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Biogen position peaked at $177M in Q1 2018.
  • 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.